Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Clinical and Translational Oncology
Published in: Clinical and Translational Oncology 12/2020

Open Access 01-12-2020 | Biomarkers | Research Article

Study of the Spanish Society of Medical Oncology (SEOM) on the access to oncology drugs and predictive biomarkers in Spain

Authors: A. Rodríguez-Lescure, F. A. de la Peña, E. Aranda, A. Calvo, E. Felip, P. Garrido, R. Vera

Published in: Clinical and Translational Oncology | Issue 12/2020

Login to get access

Abstract

Purpose

The Spanish Society of Medical Oncology (SEOM) has carried out a study to analyse the conditions of access to oncology drugs in clinical practice in Spain. For the first time, the access of predictive biomarkers has also been analyzed.

Methods

A questionnaire was sent to 146 hospitals in Spain to collect information on the process of approval of 11 oncology drugs of an unquestionable clinical benefit and five predictive biomarkers of mandatory determination for specific treatments.

Results

Results highlight the still existing differences in the access of oncology drugs, as well as the newly identified differences in the access to predictive biomarkers between Autonomous Communities (AACC) in Spain, as well as between different hospitals within the same Autonomous Community.
Conclusions
The SEOM considers it necessary to reduce the differences identified, increase homogeneity, and improve conditions of access to oncology drugs and biomarkers, and makes proposals to address these issues.
Appendix
Available only for authorised users
Literature
1.
2.
3.
4.
5.
6.
7.
Mordente A, Meucci E, Martorana GE, Silvestrini A. Cancer biomarkers discovery and validation: state of the art, problems and future perspectives. Adv Exp Med Biol. 2015;867:9–26.PubMed
8.
Cufer T, Ciuleanu TE, Berzinec P, Galffy G, Jakopovic M, Jassem J, Jovanovic D, Mihaylova Z, Ostoros G, Thallinger C, Zemanova M, Zielinski C. Access to novel drugs for non-small cell lung cancer in central and southeastern europe: a central European cooperative oncology group analysis. Oncol. 2020;25:e598–e601. https://​doi.​org/​10.​1634/​theoncologist.​2019-0523.CrossRef
9.
10.
11.
Salvador J, Aparicio J, Barón FJ, García-Campelo R, García-Carbonero R, Lianes P, Garrido P. Equity, barriers and cancer disparities: study of the Spanish Society of Medical Oncology on the access to oncologic drugs in the Spanish Regions. Clin Transl Oncol. 2017;19(3):341–56.PubMed
12.
Garrido P, Aldaz A, Calleja MA, de Alava E, Lamas MJ, Martín M, Matias-Guiu X, Palacios J, Vera R (2017) Farmacia hospitalaria: órgano oficial de expresión científica de la Sociedad Española de Farmacia Hospitalaria 41(6):688–691.
Metadata
Title
Study of the Spanish Society of Medical Oncology (SEOM) on the access to oncology drugs and predictive biomarkers in Spain
Authors
A. Rodríguez-Lescure
F. A. de la Peña
E. Aranda
A. Calvo
E. Felip
P. Garrido
R. Vera
Publication date
01-12-2020
Publisher
Springer International Publishing
Keyword
Biomarkers
Published in
Clinical and Translational Oncology / Issue 12/2020
Print ISSN: 1699-048X
Electronic ISSN: 1699-3055
DOI
https://doi.org/10.1007/s12094-020-02366-y

Other articles of this Issue 12/2020

Clinical and Translational Oncology 12/2020 Go to the issue

Research Article

hsa_circ_0121582 inhibits leukemia growth by dampening Wnt/β-catenin signaling

Review Article

The new function of circRNA: translation

Research Article

100% peer review in radiation oncology: is it feasible?

Brief Research Article

Covid-19 transmission, outcome and associated risk factors in cancer patients at the first month of the pandemic in a Spanish hospital in Madrid

Research Article

Potential roles of lymphovascular space invasion based on tumor characteristics provide important prognostic information in T1 tumors with ER and HER2 positive breast cancer

Research Article

Clinical activity of brigatinib in ROS1-rearranged non-small cell lung cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits